{"disease":{"id":"pruritus","name":"pruritus"},"drugs":{"marketed":[{"drug_id":"desonide","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verdeso","generic_name":"DESONIDE","company_name":"Padagis Us","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":50,"revenue":"2800","mechanism":""},{"drug_id":"desonide","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verdeso","generic_name":"DESONIDE","company_name":"Padagis Us","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":50,"revenue":"2800","mechanism":""},{"drug_id":"fluticasone-propionate","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"fluticasone-propionate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"phenylmercuric-nitrate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phenylmercuric nitrate","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"phenylmercuric nitrate","quality_score":null,"revenue":null,"mechanism":"Phenylmercuric nitrate works by releasing mercury ions that have antimicrobial and anti-inflammatory properties."},{"drug_id":"flumetasone","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flucorticin","generic_name":"flumetasone","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"flumetasone","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"flumetasone","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flucorticin","generic_name":"flumetasone","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"flumetasone","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"alclometasone-dipropionate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aclovate","generic_name":"ALCLOMETASONE DIPROPIONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"alclometasone-dipropionate","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aclovate","generic_name":"ALCLOMETASONE DIPROPIONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"maralixibat-hydrochloride","indication_name":"Cholestatic pruritus in patients with Alagille syndrome (ALGS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livmarli","generic_name":"maralixibat hydrochloride","company_name":"Mirum Pharma Inc","drug_phase":"marketed","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"Ileal Bile Acid Transporter Inhibitor","quality_score":57,"revenue":null,"mechanism":"Livmarli works by blocking the ileal sodium/bile acid cotransporter, which reduces the amount of bile acids reabsorbed into the bloodstream."},{"drug_id":"fludroxycortide","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordran","generic_name":"fludroxycortide","company_name":"Aqua Pharms","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"fludroxycortide","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordran","generic_name":"fludroxycortide","company_name":"Aqua Pharms","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"odevixibat","indication_name":"Pruritus in progressive familial intrahepatic cholestasis (PFIC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bylvay","generic_name":"ODEVIXIBAT","company_name":"Ipsen","drug_phase":"marketed","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"Ileal Bile Acid Transporter Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Bylvay works by blocking the ileal sodium/bile acid cotransporter, a protein that helps reabsorb bile acids in the intestines."},{"drug_id":"hydrocortisone-acetate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"benzoyl-peroxide","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzamycin","generic_name":"BENZOYL PEROXIDE","company_name":"Mayne Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"benzoyl peroxide","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"benzoyl-peroxide","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzamycin","generic_name":"BENZOYL PEROXIDE","company_name":"Mayne Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"benzoyl peroxide","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"desoximetasone","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Topicort","generic_name":"DESOXIMETASONE","company_name":"Taro","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"desoximetasone","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Topicort","generic_name":"DESOXIMETASONE","company_name":"Taro","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"fluocinolone-acetonide","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Derma-Smoothe/Fs","generic_name":"FLUOCINOLONE ACETONIDE","company_name":"Eurofarma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"fluocinolone-acetonide","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Derma-Smoothe/Fs","generic_name":"FLUOCINOLONE ACETONIDE","company_name":"Eurofarma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"clocortolone-pivalate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cloderm","generic_name":"CLOCORTOLONE PIVALATE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"clocortolone-pivalate","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cloderm","generic_name":"CLOCORTOLONE PIVALATE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"ulobetasol-propionate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultravate","generic_name":"ulobetasol propionate","company_name":"Ranbaxy","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"ulobetasol propionate","quality_score":51,"revenue":null,"mechanism":"Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation."},{"drug_id":"ulobetasol-propionate","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultravate","generic_name":"ulobetasol propionate","company_name":"Ranbaxy","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"ulobetasol propionate","quality_score":51,"revenue":null,"mechanism":"Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation."},{"drug_id":"betamethasone-dipropionate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diprolene","generic_name":"BETAMETHASONE DIPROPIONATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":"Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system."},{"drug_id":"betamethasone-dipropionate","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diprolene","generic_name":"BETAMETHASONE DIPROPIONATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":"Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system."},{"drug_id":"difelikefalin","indication_name":"Pruritus associated with chronic kidney disease (CKD-aP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Korsuva","generic_name":"DIFELIKEFALIN","company_name":"Vifor Intl","drug_phase":"marketed","molecular_target":"Kappa-type opioid receptor","drug_class":"Kappa Opioid Receptor Agonist","quality_score":48,"revenue":null,"mechanism":"Korsuva works by activating the kappa-type opioid receptor, which helps to reduce itching."},{"drug_id":"betamethasone-valerate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone Valerate","generic_name":"BETAMETHASONE VALERATE","company_name":"Fougera Pharms Inc","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-valerate","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone Valerate","generic_name":"BETAMETHASONE VALERATE","company_name":"Fougera Pharms Inc","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sudafed PE","generic_name":"phenylephrine","company_name":"Generic (multiple manufacturers)","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor","drug_class":"Alpha-1 adrenergic agonist (decongestant/vasopressor)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"phenylephrine-bitartrate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenergan Vc W/ Codeine","generic_name":"PHENYLEPHRINE BITARTRATE","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"lignocaine","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lignocaine","company_name":"University of Malaya","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lidocaine-hydrochloride","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lignospan Forte","generic_name":"Lidocaine Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"neuronal membrane ionic channels","drug_class":"local anesthetic, amide type","quality_score":68,"revenue":null,"mechanism":"Lidocaine stabilizes neuronal membrane by inhibiting ionic fluxes required for impulse initiation and conduction."},{"drug_id":"nasonex","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"nasonex","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"methylprednisolone","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"nalfurafine","indication_name":"Severe Pruritus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remitch","generic_name":"NALFURAFINE","company_name":"","drug_phase":"marketed","molecular_target":"Kappa-type opioid receptor","drug_class":"nalfurafine","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-benzoate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone 17-Benzoate","generic_name":"BETAMETHASONE BENZOATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-benzoate","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone 17-Benzoate","generic_name":"BETAMETHASONE BENZOATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cholestyramine","indication_name":"Biliary Obstruction with Pruritus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Questran Light","generic_name":"CHOLESTYRAMINE","company_name":"Bristol Myers","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"flixotide","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"flixotide","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"nemolizumab","indication_name":"Pruritus associated with atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitchga","generic_name":"NEMOLIZUMAB","company_name":"Maruho Co., Ltd.","drug_phase":"marketed","molecular_target":"Interleukin-31 receptor subunit alpha","drug_class":"Interleukin-31 Receptor alpha Antagonist [EPC]","quality_score":35,"revenue":null,"mechanism":"Nemolizumab works by binding to the interleukin-31 receptor subunit alpha, blocking the action of interleukin-31 and reducing inflammation and itching."},{"drug_id":"fluocinonide","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lidex","generic_name":"FLUOCINONIDE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"fluocinonide","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lidex","generic_name":"FLUOCINONIDE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"halcinonide","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Halog","generic_name":"HALCINONIDE","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"halcinonide","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Halog","generic_name":"HALCINONIDE","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ammonium-lactate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lac-Hydrin","generic_name":"AMMONIUM LACTATE","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"alpha-Hydroxy Acid [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"ammonium-lactate","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lac-Hydrin","generic_name":"AMMONIUM LACTATE","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"alpha-Hydroxy Acid [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"prednicarbate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dermatop","generic_name":"PREDNICARBATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"prednicarbate","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dermatop","generic_name":"PREDNICARBATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mometasone-furoate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"mometasone-furoate","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe anogenital pruritus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe anogenital pruritus in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"diflorasone-diacetate","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Psorcon","generic_name":"DIFLORASONE DIACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"diflorasone-diacetate","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Psorcon","generic_name":"DIFLORASONE DIACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"amcinonide","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclocort","generic_name":"AMCINONIDE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"amcinonide","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclocort","generic_name":"AMCINONIDE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"betamethasone","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"benoxyl","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Benoxyl","company_name":"Aier School of Ophthalmology, Central South University","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"benoxyl","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Benoxyl","company_name":"Aier School of Ophthalmology, Central South University","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pramocaine","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pramocaine","company_name":"","drug_phase":"unknown","molecular_target":"Sigma non-opioid intracellular receptor 1, Sodium channel alpha subunits; brain (Types I, II, III), Membrane-associated progesterone receptor component 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lidocain","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lidocain","company_name":"Bayer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xylocain","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xylocain","company_name":"Saint-Joseph University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"livmarli","indication_name":"Cholestatic pruritus in patients with Alagille syndrome (ALGS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Livmarli","company_name":"Mirum Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mometasone","indication_name":"Pruritus ani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"maralixibat-hydrochloride","indication_name":"Cholestatic pruritus in Alagille syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livmarli","generic_name":"maralixibat hydrochloride","company_name":"Mirum Pharma Inc","drug_phase":"marketed","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"Ileal Bile Acid Transporter Inhibitor","quality_score":57,"revenue":null,"mechanism":"Livmarli works by blocking the ileal sodium/bile acid cotransporter, which reduces the amount of bile acids reabsorbed into the bloodstream."},{"drug_id":"mometasone","indication_name":"Pruritus of genital organs","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"maralixibat-hydrochloride","indication_name":"Cholestatic pruritus in PFIC","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livmarli","generic_name":"maralixibat hydrochloride","company_name":"Mirum Pharma Inc","drug_phase":"marketed","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"Ileal Bile Acid Transporter Inhibitor","quality_score":57,"revenue":null,"mechanism":"Livmarli works by blocking the ileal sodium/bile acid cotransporter, which reduces the amount of bile acids reabsorbed into the bloodstream."},{"drug_id":"cholestyramine","indication_name":"Pruritus with Partial Biliary Obstruction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Questran Light","generic_name":"CHOLESTYRAMINE","company_name":"Bristol Myers","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxyzine-pamoate","indication_name":"Management of pruritus due to allergic conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HYDROXYZINE PAMOATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":94,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05524467","title":"Cross-sectional Study to Assess Prevalence and Burden of CKD-associated Pruritus in Haemodialysis Patients","phase":"","overall_status":"COMPLETED","enrollment_count":3100,"lead_sponsor_name":"Vifor (International) Inc.","has_results":false},{"nct_id":"NCT03540160","title":"Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":558,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT04490109","title":"B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":547,"lead_sponsor_name":"AOBiome LLC","has_results":true},{"nct_id":"NCT05135390","title":"A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients with Chronic Kidney Disease-Associated Pruritus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":545,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05837988","title":"Construction of Symptom Network in Maintenance Hemodialysis Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":517,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT03636269","title":"CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":473,"lead_sponsor_name":"Cara Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03824886","title":"Enhancing SKIN Health and Safety in Aged CARE","phase":"NA","overall_status":"COMPLETED","enrollment_count":405,"lead_sponsor_name":"PD Dr. Jan Kottner","has_results":false},{"nct_id":"NCT05415969","title":"CKD-aP Among Adults on Dialysis in Switzerland","phase":"","overall_status":"COMPLETED","enrollment_count":401,"lead_sponsor_name":"University of Applied Sciences of Western Switzerland","has_results":false},{"nct_id":"NCT04018027","title":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":401,"lead_sponsor_name":"Cara Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03422653","title":"A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":378,"lead_sponsor_name":"Cara Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04415034","title":"Scalp Pruritus Measurement Using Visual Analog Scale and 5-d Itch Scale in Children With Pediculosis Capitis","phase":"","overall_status":"COMPLETED","enrollment_count":357,"lead_sponsor_name":"Indonesia University","has_results":false},{"nct_id":"NCT03677401","title":"Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT03281538","title":"Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":288,"lead_sponsor_name":"Cara Therapeutics, Inc.","has_results":true},{"nct_id":"NCT05387707","title":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":287,"lead_sponsor_name":"Cara Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05342623","title":"A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":286,"lead_sponsor_name":"Cara Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03546816","title":"Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":285,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT05263206","title":"Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":284,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03832140","title":"Frequency and Characteristics of Pruritus in Patients With Monoclonal Gammopathy","phase":"","overall_status":"COMPLETED","enrollment_count":281,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT03218501","title":"A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"Sanwa Kagaku Kenkyusho Co., Ltd.","has_results":false},{"nct_id":"NCT03617536","title":"A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"Cara Therapeutics, Inc.","has_results":true},{"nct_id":"NCT05885737","title":"Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Vifor Fresenius Medical Care Renal Pharma","has_results":true},{"nct_id":"NCT05075408","title":"To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":258,"lead_sponsor_name":"Galderma R&D","has_results":true},{"nct_id":"NCT01951274","title":"VPD-737 for Treatment of Chronic Pruritus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":257,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":false},{"nct_id":"NCT06290375","title":"A Study of HSK21542 in a Peritoneal Dialysis Pruritus Population.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Xizang Haisco Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT03802617","title":"A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":247,"lead_sponsor_name":"Kissei Pharmaceutical Co., Ltd.","has_results":true},{"nct_id":"NCT04950127","title":"Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":238,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03841331","title":"Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT03998163","title":"CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"Cara Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06435299","title":"Efficacy and Tolerance of Cannabidiol in Patients with Severe Pruritus: a Multicenter, Double-blind, Randomized, Placebo-controlled Study","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":218,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT05978063","title":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":214,"lead_sponsor_name":"Cara Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03322137","title":"Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"Sienna Biopharmaceuticals","has_results":false},{"nct_id":"NCT03343639","title":"Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT06188546","title":"Propofol for Prophylaxis of Morphine Induced Pruritis in Caesarean Section","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT03673878","title":"Prevalence of a Localized or Diffuse Pruritus in a Population With One or Several, Primitive or Secondary, Brain Tumor(s)","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04949893","title":"Causes of Chronic Pruritus","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT06446310","title":"Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":194,"lead_sponsor_name":"Qilu Pharmaceutical (Hainan) Co., Ltd.","has_results":false},{"nct_id":"NCT03317301","title":"Evaluate the Efficacy and Safety of HL151 Versus Talion Tab. in Pruritus Cutaneus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":189,"lead_sponsor_name":"Hanlim Pharm. Co., Ltd.","has_results":false},{"nct_id":"NCT04365244","title":"Pruritus and Melanoma and Cutaneous Carcinomas Treated With Immunotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":181,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04711603","title":"A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":178,"lead_sponsor_name":"Kissei Pharmaceutical Co., Ltd.","has_results":true},{"nct_id":"NCT05678309","title":"Establishment of a Patient Library in Patients With Pruritus Sine Materia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":175,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04018209","title":"Aquagenic Pruritus in Myeloproliferative Neoplasms","phase":"","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT05162430","title":"Inhibitory Effect of Propofol on Perineal Pruritus in Patients Undergoing Day Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Yangzhou University","has_results":false},{"nct_id":"NCT05870865","title":"A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"Formation Bio, Inc.","has_results":true},{"nct_id":"NCT04693195","title":"A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Bellus Health Inc. - a GSK company","has_results":false},{"nct_id":"NCT06225323","title":"Effect of Lidocaine Infusion on Neuraxial Opioid-induced Pruritus After Cesarean Section","phase":"NA","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Aswan University","has_results":false},{"nct_id":"NCT03035942","title":"Quality of Recovery After Dexamethasone, Ondansetron or Placebo Intrathecal Morphine Administration","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Pontificia Universidade Catolica de Sao Paulo","has_results":true},{"nct_id":"NCT04728984","title":"A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":135,"lead_sponsor_name":"Shenyang Sunshine Pharmaceutical Co., LTD.","has_results":false},{"nct_id":"NCT04470154","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT04706975","title":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Cara Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03751111","title":"Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}